Search

Your search keyword '"Bourhis, Jean Henri"' showing total 6 results
Start Over Author "Bourhis, Jean Henri" Journal leukemia & lymphoma
6 results on '"Bourhis, Jean Henri"'

2. A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience

Author

Saleh, Khalil, primary, Danu, Alina, additional, Koscielny, Serge, additional, Legoupil, Clémence, additional, Pilorge, Sylvain, additional, Castilla-Llorente, Cristina, additional, Ghez, David, additional, Lazarovici, Julien, additional, Michot, Jean-Marie, additional, Khalife-Saleh, Nadine, additional, Lapierre, Valerie, additional, Alenxandrova, Kamelia, additional, Arfi-Rouche, Julia, additional, Bourhis, Jean-Henri, additional, and Ribrag, Vincent, additional

Published
2017
Full Text
View/download PDF

3. A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.

Author

Saleh, Khalil, Danu, Alina, Koscielny, Serge, Legoupil, Clémence, Pilorge, Sylvain, Castilla-Llorente, Cristina, Ghez, David, Lazarovici, Julien, Michot, Jean-Marie, Khalife-Saleh, Nadine, Lapierre, Valerie, Alenxandrova, Kamelia, Arfi-Rouche, Julia, Bourhis, Jean-Henri, and Ribrag, Vincent

Subjects
CARMUSTINE, ETOPOSIDE, MELPHALAN, DRUG therapy, STEM cell transplantation, HODGKIN'S disease
Abstract

The combination of carmustine, etoposide, aracytin, and melphalan(BEAM) conditioning regimen in autologous stem-cell transplantation (ASCT) is widely used in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma. It is also an option in patients with very-high risk aggressive NHL in first complete remission (CR). Recently, a phase Ib-II feasibility study using bendamustine replacing carmustine (BCNU) was reported. We report herein a safety and efficacy analysis of bendamustine-EAM (BeEAM) with a control BEAM counterpart paired cohort (1/2). One hundred and two patients were analyzed. Overall survival (OS) and progression-free survival (PFS) were not reached and seemed to be comparable between both groups. However, grade III or greater diarrhea was significantly higher in BeEAM patients (44 vs. 15%, p = .002). The median number of days with fever >38 °C was significantly higher in BeEAM group (5.5 vs. 2, p < .001). This case-control study suggests that BeEAM followed by ASCT using bendamustine at 100 mg/m2/d is effective but has a different toxicity profile than the BEAM regimen. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

4. Mobilization of peripheral blood progenitor cells after DHAP regimen with or without rituximab: A large multicenter comparative study in patients with malignant lymphoma

Author

de Latour, Régis Peffault, primary, Chaoui, Driss, additional, Bourhis, Jean-Henri, additional, Belhocine, Ramdane, additional, Park, Sophie, additional, Legrand, Ollivier, additional, Brault, Philippe, additional, Rio, Bernard, additional, Heshmati, F., additional, Assouad, Sabine, additional, and Decaudin, Didier, additional

Published
2007
Full Text
View/download PDF

5. Gallium Scan in the Evaluation of Post Chemotherapy Mediastinal Residual Masses of Aggressive Non-Hodgkin's Lymphoma

Author

Ulusakarya, Ayhan, primary, Lumbroso, Jean, additional, Casiraghi, Odile, additional, Koscielny, Serge, additional, Vantelon, Jean-Marie, additional, Girinsky, Theo, additional, Tardivon, Anne, additional, Bourhis, Jean-Henri, additional, Dartevelle, Philippe, additional, Pico, Jose-Luis, additional, and Munck, Jean-Nicolas, additional

Published
1999
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results